---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-235298"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2023-09-14T23:59:59+00:00"
generated_at: "2026-06-10T17:39:29.914264+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma director Aaron Fletcher resigns from board effective Oct 9, 2023

## Summary
- Aaron Fletcher notified Cue Biopharma of resignation from Board and all committees.
- Resignation effective October 9, 2023, is not due to any disagreement with the Company.
- No replacement or successor named; board size adjusted.

## SEC filing metadata
- accession: 0001193125-23-235298
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2023-09-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000119312523235298/0001193125-23-235298-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000119312523235298/d540189d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-235298
- JSON: https://secwatch.observer/filing/0001193125-23-235298.json
- Plain text: https://secwatch.observer/filing/0001193125-23-235298.txt

## Key facts
- Executive change
  Aaron Fletcher resigned as Member of the Board of Directors at Cue Biopharma, Inc..
  - Action: resigned
  - Role: Member of the Board of Directors
  source text: On September 12, 2023, Aaron Fletcher notified Cue Biopharma, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company (the “Board”) and all committees thereof, effective on October 9, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000119312523235298/0001193125-23-235298-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.